jRCT2071250154
Recruiting
Not Applicable
A phase I clinical trial of KSP-0576
Not provided0 sites256 target enrollmentStarted: TBD
Overview
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 256
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
Eligibility Criteria
- Ages
- 18age old over to 65age old not (—)
- Sex
- All
Inclusion Criteria
- •At the time of informed consent, male aged >=18 and =<45 years or females aged >=50 and <65 years at least 12 months after the last menstrual period.
- •Japanese participants with a BMI >=18.5 to <25 kg/m^2 or Caucasian participants with a BMI >=18.5 to <30 kg/m^
- •Males who body weight >=50 to <90 kg and females who body weight >=45 to <90 kg.
Exclusion Criteria
- •Participants with abnormal findings on medical examination, vital signs, or 12-lead ECG, judged by the principal investigator or subinvestigator to be clinically significant.
Investigators
Similar Trials
Not yet recruiting
Phase 1
A study testing a new treatment called TK-6302 for the first time in people with advanced cancers that have a genetic marker called HLA-A02:01 and a tumour protein called PRAME.2025-521603-46-00T-Knife GmbH24
Recruiting
Phase 2
A Phase II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With MET AbnormalitiesNCT07308106Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.60
Not yet recruiting
Phase 1
SKB105 for Injection in Advanced Solid TumorsNCT07380386Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.256
Not yet recruiting
Phase 1
A Phase 1 study of GSK5764227 in participants with advanced solid tumors2024-513663-10-01Glaxosmithkline Research & Development Limited, Glaxosmithkline Research & Development Limited112
Not yet recruiting
Phase 2
The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent GliomaNCT07386002T-MAXIMUM Pharmaceutical Inc40